查詢結果分析
相關文獻
- Renal Cell Carcinoma Presented as a Traumatic Ruptured Kidney
- Tumor Angiogenesis and Metastasis: Correlation in Invasive Renal Cell Carcinoma
- Findings of Persistent Microscopic Hematuria in a Cancer Prevention and Early Detection Program
- Detection of Serum Anti-p53 Antibody in Patients with Renal Cell Carcinoma
- Removal of Renal Cell Carcinoma Extending into Supradiaphragmatic Inferior Vena Cava Using Cardiopulmonary Bypass with Deep Hypothermic Circulatory Arrest--A Report of 2 Cases
- 舌之轉移性腎細胞癌--病例報告
- 轉移性腎細胞癌的診斷與治療
- Renal Cell Carcinoma: Unusual Pediatric Renal Tumors
- Incidental Renal Cell Carcinoma: Experience at National Cheng Kung University Hospital
- 腎細胞癌於口內轉移之病例報告
頁籤選單縮合
題 名 | 腎細胞癌的分子標靶藥品治療=Molecularly Targeted Therapy for the Treatment of Renal Cell Carcinoma |
---|---|
作 者 | 施雅分; 廖淑貞; 簡素玉; 林逸祥; | 書刊名 | 藥學雜誌 |
卷 期 | 29:4=117 2013.12[民102.12] |
頁 次 | 頁44-49 |
分類號 | 418.31 |
關鍵詞 | 腎細胞癌; Sorafenib; Sunitinib; Pazopanib; Temsirolimus; Everolimus; |
語 文 | 中文(Chinese) |
中文摘要 | 腎細胞癌是腎臟最常見的惡性腫瘤,衛福部迄今共核准 5種標靶藥品用來治療晚期/轉移性腎細胞癌,依作用機轉分成兩大類:第一類是酪胺酸激酶抑制劑 (tyrosine kinase inhibitors, TKIs),包括 sorafenib、sunitinib、pazopanib;第二類是 mTOR (mammalian target of rapamycin)抑制劑,包括 temsirolimus、everolimus。目前臨床上將 sunitinib、pazopanib、temsirolimus視為治療晚期腎細胞癌的第一線用藥,而 sorafenib和 everolimus屬於第二線用藥。因為標靶藥品的出現,可以為晚期腎細胞癌病人之治療帶來一道曙光。 |
英文摘要 | Renal cell carcinoma (RCC) is the most common renal cancer. Five targeted agents for the treatment of advanced or metastatic RCC have been approved by the Taiwan Food and Drug Administration and in clinical use: the tyrosine kinase inhibitors (sorafenib, sunitinib and pazopanib) and the mammalian target of rapamycin inhibitors (mTOR) (temsirolimus and everolimus). Sunitinib, pazopanib, temsirolimus are the first-line and sorafenib, everolimus are the second-line targeted therapy in patients with advanced RCC. Currently, these targeted agents have been translated into clinical treatment options in advanced RCC. |
本系統中英文摘要資訊取自各篇刊載內容。